Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market - Global Industry Trend Analysis 2012 to 2017 and Forecast 2017 - 2025


#10500

Persistence Market Research

$ 4900

Postural orthostatic tachycardia syndrome is an autonomic nervous system disorder having symptoms such as, light-headedness, sweating, anxiety, fatigue, tremors, palpitation and orthostatic intolerance. Postural orthostatic tachycardia syndrome is a category of disease rather than a single illness. In this condition patient’s heart rate increase by 30 beats per minute in standing position reaching to more than 120 beats per minute as compare to resting or lying position. Patients with postural orthostatic tachycardia syndrome have change in blood pressure which can fluctuate in either direction means hypertension or hypotension. Postural orthostatic tachycardia syndrome can be classified in primary forms and secondary forms. This condition can limit the patient’s life and obstruct him performing daily activities, e.g. feeding, household work, walking etc. Usually, this condition affect age group of 12-50 years with females being affected five times more than the males. Postural orthostatic tachycardia syndrome can be treated using both pharmacological and non-pharmacological measure. Pharmacological measures are used when non-pharmacological measures are unable to manage postural orthostatic tachycardia syndrome.

Postural Orthostatic Tachycardia Syndrome Treatment Market: Drivers and Restraints

Increasing awareness among physicians regarding the postural orthostatic tachycardia syndrome is expected to growth of treatment market. Due to mystifying nature of postural orthostatic tachycardia syndrome various international bodies such as, MyHeart are conducting research and surveys to understand the nature of syndrome for proper diagnosis and treatment. Increasing focus of these international bodies to study this condition is expected to fuel the growth of postural orthostatic tachycardia syndrome treatment market. Unavailability of specific treatment option can serve as restraint. Misdiagnosis of postural orthostatic tachycardia syndrome as anxiety, panic attack and depression is also a hindrance in the growth of market.

Postural Orthostatic Tachycardia Syndrome Treatment Market: Segmentation

The global postural orthostatic tachycardia syndrome treatment market can be segmented by End User and Region.

On the basis of end user the global postural orthostatic tachycardia syndrome treatment market can be segmented as:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Research Institutes

Postural Orthostatic Tachycardia Syndrome Treatment Market: Overview

Postural orthostatic tachycardia syndrome treatment market is expected to show significant growth over the forecast period owning to factors such as, increasing awareness and diagnosis. Unavailability of the specific treatment is a hindrance for the growth of postural orthostatic tachycardia syndrome but few drugs are under clinical trials which are expected to get marketing approval over the forecast period and fuel the growth of postural orthostatic tachycardia syndrome treatment market. Availability off-label treatment option is also expected to boost the growth. Various research institutes and medical institutions are developing specific drugs which are expected to fuels the growth of postural orthostatic tachycardia syndrome market.

Postural Orthostatic Tachycardia Syndrome Treatment Market: Region Wise Outlook

Geographically, the global orthostatic tachycardia syndrome treatment market can be segmented into regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to be biggest and fastest growing postural orthostatic tachycardia syndrome treatment market owning to increasing clinical trials in the region, increasing awareness and better healthcare infrastructures. Followed by which is Europe. Asia Pacific is also expected to show a slight growth in postural orthostatic tachycardia treatment market due to higher prevalence of cardiac disease in this region. Increasing awareness and diagnosis is also expected to drive the growth in this region.

Postural Orthostatic Tachycardia Syndrome Treatment Market: Key Players

Some of the market participants in the global postural orthostatic syndrome treatment market are Pfizer, Inc., Novartis AG, AstraZeneca, Merck & Co.,Inc., Sanofi S.A., Daiichi Sankyo Company, Limited and Bayer AG. Companies in collaboration with research institutes are investing in research and development for specific drug development to treat postural orthostatic tachycardia syndrome.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.